Rivella Laboratory
Children's Hospital of Philadelphia · University of Pennsylvania
The Rivella Laboratory studies the pathophysiology of erythroid and iron disorders and develops gene therapies to treat them. The laboratory is located at the Children's Hospital of Philadelphia, the nation's first hospital devoted exclusively to the care of children.
About the Laboratory
The Rivella Lab creates next-generation lentiviral vectors to cure hemoglobinopathies, including sickle cell disease. More recently, the laboratory expanded its focus to developing tools for RNA delivery to the bone marrow and liver — gene editing and RNA therapies — to treat hematological and metabolic disorders.
The team is a leader in the characterization of erythroid and iron disorders, including beta-thalassemia, and has made significant contributions to the scientific literature on red blood cells and on how manipulating red cell production can lead to the development of new disease-modifying therapies.
Research Overview
The laboratory team is experts in the use of lentiviral vectors for modulation of gene expression and gene transfer for the cure of hemoglobinopathies, and in the pathophysiology and genetics of several murine models of hematopoiesis, inflammation, and iron-related disorders.
Investigators in the lab generate lentiviral vectors aimed at curing beta-thalassemia and sickle cell anemia, and work with various disease models of hemoglobinopathies, as well as patient cells, to characterize these vectors.
Alongside the hemoglobinopathies, the team studies the seminal factors contributing to the pathophysiology of hematopoiesis, inflammation and iron-related disorders:
- Sideroblastic and dyserythropoietic anemias
- Polycythemia vera
- Anemia of inflammation
- Hemochromatosis
Across beta-thalassemia, alpha-thalassemia, polycythemia vera, hemochromatosis and anemia of inflammation, the team studies the influential factors that contribute to morbidity and mortality — hepcidin, interleukin-6, ferroportin, the phosphokinase JAK2 and macrophages — with the goal of developing novel therapies. Based on this work, the lab is developing or contributing to the characterization of novel therapeutics.
Gene Therapy and RNA Delivery
Scientific findings from the Rivella Lab paved the way for gene therapy trials for hemoglobinopathies.
The team generated the first adult murine models of XLSA, CDA1, and alpha- and beta-thalassemia major, as well as the first lentiviral vectors that corrected hemoglobin synthesis in these diseases. An advanced vector generated in the laboratory gained FDA approval for the cure of beta-thalassemia.
The laboratory has since expanded its focus to developing tools for RNA delivery — gene editing and RNA therapies — to make bone marrow transplant safer and to treat hematological and metabolic disorders.
Translational Impact
The Rivella Lab was involved in the characterization of luspatercept-aamt (Reblozyl, Celgene Corporation, a Bristol Myers Squibb Company) and was the first to propose the use of hepcidin agonists or inducers for beta-thalassemia, hemochromatosis, and polycythemia vera. Through these translational efforts, the lab’s research helped to bring life-changing medical advancements to patients in need.
- Luspatercept has been approved to improve red cell production in beta-thalassemia.
- Rusfertide, a hepcidin agonist, has been approved by the FDA to replace phlebotomy without causing iron deficiency in patients with polycythemia vera.
Iron Metabolism and Red Cell Production
The team explores iron metabolism and red cell production in normal erythropoiesis, beta-thalassemia, hemochromatosis and polycythemia vera. This work has shown that two different forms of monoferric transferrin are functionally distinct in regulating hepcidin and erythropoietin responsiveness. These discoveries may lead to novel translational applications to treat ineffective erythropoiesis in beta-thalassemia.
The lab has also shown that the hepatic peptide hepcidin, which controls iron absorption, plays an important role in the progressive iron overload observed in beta-thalassemia — the most salient and ultimately fatal complication of the disease. In beta-thalassemia, ineffective erythropoiesis represses hepcidin, leading to iron overload.
The team therefore hypothesizes that increased hepcidin expression reduces iron burden in beta-thalassemia. Increased hepcidin levels appeared to prevent iron overload, improve red cell production and ameliorate anemia in animal models of beta-thalassemia. The same approach can prevent iron overload in hemochromatosis and normalize hematocrit in polycythemia vera.
Ineffective Erythropoiesis
Patients with beta-thalassemia experience excessive production of immature erythroid cells. A study from the Rivella Lab suggests that erythropoiesis in beta-thalassemia is characterized by enhanced expression of genes that promote survival and cell proliferation.
The team is now evaluating the role of these proteins in this disorder and characterizing new therapeutics that modulate erythropoiesis. The lab showed that iron restriction or JAK2 inhibitors are effective in reversing splenomegaly, while modulation of the transforming growth factor beta signaling pathway improves anemia in beta-thalassemia.
The laboratory is further characterizing these and other pathways that are dysregulated in this and other disorders characterized by ineffective erythropoiesis, such as alpha-thalassemia and myelodysplastic disorders.
Collaboration Across CHOP and Penn
The Rivella Lab works in tandem with the Comprehensive Center for the Cure of Sickle Cell Disease and Other Red Blood Cell Disorders (CuRED), a CHOP-designated Frontier Program that aims to develop and deliver novel gene therapies and stem cell transplants to patients in a family-centered clinic.
The Rivella lab also collaborates with the Penn Institute for RNA Innovation.
Where We Work
Since 1855, CHOP has been the birthplace for many dramatic firsts in pediatric medicine. The Hospital has fostered medical discoveries and innovations that have improved pediatric healthcare and saved countless children’s lives.
Our laboratory is located in the Leonard and Madlyn Abramson Pediatric Research Center and in the Colket Translational Research Building.